155 related articles for article (PubMed ID: 26238010)
1. PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes.
Even AJ; van der Stoep J; Zegers CM; Reymen B; Troost EG; Lambin P; van Elmpt W
Radiother Oncol; 2015 Aug; 116(2):281-6. PubMed ID: 26238010
[TBL] [Abstract][Full Text] [Related]
2. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
[TBL] [Abstract][Full Text] [Related]
3. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
4. Impact of tumour motion compensation and delineation methods on FDG PET-based dose painting plan quality for NSCLC radiation therapy.
Thomas HM; Kinahan PE; Samuel JJE; Bowen SR
J Med Imaging Radiat Oncol; 2018 Feb; 62(1):81-90. PubMed ID: 29193781
[TBL] [Abstract][Full Text] [Related]
5. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
Yap ML; Sun A; Higgins J; Clarke K; Marshall A; Becker N; Le LW; Vines DC; Bezjak A; Bissonnette JP
Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e199-e205. PubMed ID: 27637725
[TBL] [Abstract][Full Text] [Related]
6. Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: practical implications of using a broad or sharp brush.
Meijer G; Steenhuijsen J; Bal M; De Jaeger K; Schuring D; Theuws J
Radiother Oncol; 2011 Sep; 100(3):396-401. PubMed ID: 21955663
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
Møller DS; Nielsen TB; Brink C; Hoffmann L; Lutz CM; Drøgemüller Lund M; Hansen O; Schytte T; Khalil AA; Knap MM; Nyhus CH; Ottosson W; Sibolt P; Borissova S; Josipovic M; Persson G; Appelt AL
Radiother Oncol; 2017 Aug; 124(2):311-317. PubMed ID: 28688525
[TBL] [Abstract][Full Text] [Related]
8. Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.
Lee E; Zeng J; Miyaoka RS; Saini J; Kinahan PE; Sandison GA; Wong T; Vesselle HJ; Rengan R; Bowen SR
Med Phys; 2017 Jul; 44(7):3418-3429. PubMed ID: 28453861
[TBL] [Abstract][Full Text] [Related]
9. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
[TBL] [Abstract][Full Text] [Related]
10. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
[TBL] [Abstract][Full Text] [Related]
11. Late-Course Adaptive Adjustment Based on Metabolic Tumor Volume Changes during Radiotherapy May Reduce Radiation Toxicity in Patients with Non-Small Cell Lung Cancer.
Xiao L; Liu N; Zhang G; Zhang H; Gao S; Fu Z; Wang S; Yu Q; Yu J; Yuan S
PLoS One; 2017; 12(1):e0170901. PubMed ID: 28125698
[TBL] [Abstract][Full Text] [Related]
12. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
13. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients.
Møller DS; Khalil AA; Knap MM; Muren LP; Hoffmann L
Acta Oncol; 2011 Aug; 50(6):883-8. PubMed ID: 21767188
[TBL] [Abstract][Full Text] [Related]
14. Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy - the influence of the choice of the reference region and conversion function.
Lindblom E; Dasu A; Uhrdin J; Even A; van Elmpt W; Lambin P; Wersäll P; Toma-Dasu I
Acta Oncol; 2017 Jun; 56(6):819-825. PubMed ID: 28464740
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.
van Elmpt W; Zegers CML; Reymen B; Even AJG; Dingemans AC; Oellers M; Wildberger JE; Mottaghy FM; Das M; Troost EGC; Lambin P
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):240-248. PubMed ID: 26338178
[TBL] [Abstract][Full Text] [Related]
16. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
van Elmpt W; De Ruysscher D; van der Salm A; Lakeman A; van der Stoep J; Emans D; Damen E; Öllers M; Sonke JJ; Belderbos J
Radiother Oncol; 2012 Jul; 104(1):67-71. PubMed ID: 22483675
[TBL] [Abstract][Full Text] [Related]
17. Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription.
Ureba A; Lindblom E; Dasu A; Uhrdin J; Even AJG; van Elmpt W; Lambin P; Wersäll P; Toma-Dasu I
Acta Oncol; 2018 Apr; 57(4):485-490. PubMed ID: 29141489
[TBL] [Abstract][Full Text] [Related]
18. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
[TBL] [Abstract][Full Text] [Related]
19. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.
Feng M; Kong FM; Gross M; Fernando S; Hayman JA; Ten Haken RK
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1228-34. PubMed ID: 19251094
[TBL] [Abstract][Full Text] [Related]
20. Computational delineation and quantitative heterogeneity analysis of lung tumor on 18F-FDG PET for radiation dose-escalation.
Wang X; Cui H; Gong G; Fu Z; Zhou J; Gu J; Yin Y; Feng D
Sci Rep; 2018 Jul; 8(1):10649. PubMed ID: 30006600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
